Kwality Pharma Q1 FY27 results: revenue up 46 percent, PAT up 119 percent YoY
KPL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 19.9 pts more than Nifty Microcap 250 and 19.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Kwality Pharmaceuticals reported consolidated Q1 FY27 revenue of Rs 162 crore, up 46 percent YoY from Rs 112 crore. EBITDA rose 13 percent to Rs 41 crore with margins expanding to 25.3 percent from 21.9 percent. PAT surged 119 percent to Rs 26 crore, with EPS at Rs 24.69 versus Rs 11.50. Management raised FY27 guidance: revenue above Rs 700 crore, EBITDA Rs 189 to 196 crore, PAT above Rs 109 crore. Auditor issued an unmodified limited review report.
Strong beat across revenue, margins and earnings; raised FY27 guidance signals management confidence and points to positive momentum.